{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T13:00:32Z","timestamp":1785502832756,"version":"3.56.0"},"reference-count":88,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T00:00:00Z","timestamp":1785456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>\n                    Myocardial hypertrophy is initially an adaptive response to mechanical, neurohumoral, or metabolic stress, but persistent hypertrophy increases the risk of heart failure, arrhythmia, and death. Metabolic remodeling is now recognized as an early driver rather than a passive consequence of increased workload. This review aims to summarize recent advances in metabolic abnormalities in myocardial hypertrophy, focusing on pathophysiological mechanisms, biomarker implications, therapeutic opportunities, and future directions. Current evidence establishes that hypertrophic myocardium exhibits substrate inflexibility, impaired fatty acid oxidation, increased glycolysis with anaplerotic rerouting, mitochondrial calcium and quality-control defects, NAD\n                    <jats:sup>+<\/jats:sup>\n                    -sirtuin disruption, redox stress and ferroptosis, branched-chain amino acid accumulation, and ketone body adaptation. These abnormalities interact with canonical growth pathways including AMPK, mTOR, PKA, YAP, STAT3, ERR, SIRT3\/SIRT5\/SIRT6, and inflammatory programs. In biomarker research, metabolomics has moved from single metabolites toward integrated panels combining circulating acylcarnitines, amino acids, ketones, redox markers, and imaging-derived hypertrophy; however, interpretation remains strongly context-dependent on etiology, disease stage, sex, renal function, diabetes, and therapy. Therapeutically, phenotype-specific strategies\u2014such as NAD\n                    <jats:sup>+<\/jats:sup>\n                    repletion, SIRT activation, BCAA catabolism modulation, and ferroptosis inhibition\u2014are emerging but require biomarker-guided trials. Despite these advances, critical challenges remain: distinguishing adaptive compensation from maladaptive remodeling, validating tissue-to-plasma concordance, establishing longitudinal human cohorts with serial metabolomics, and developing harmonized multi-omics pipelines. By addressing these core issues, this review provides a comprehensive, clinically oriented perspective on the current state and future trajectory of metabolic research in myocardial hypertrophy, emphasizing the need for biomarker-enriched interventions before irreversible remodeling occurs.\n                  <\/jats:p>","DOI":"10.3389\/fcvm.2026.1912835","type":"journal-article","created":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T12:04:45Z","timestamp":1785499485000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Research progress on metabolic abnormalities in myocardial hypertrophy"],"prefix":"10.3389","volume":"13","author":[{"given":"Xueru","family":"Liu","sequence":"first","affiliation":[{"name":"Tumor ImmunoMetabolism Institute (TIMI), Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University","place":["Zhuzhou, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlin","family":"Liu","sequence":"additional","affiliation":[{"name":"Shaoyang Central Hospital","place":["Shaoyang, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Huang","sequence":"additional","affiliation":[{"name":"Tumor ImmunoMetabolism Institute (TIMI), Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University","place":["Zhuzhou, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Ouyang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China","place":["Hefei, Anhui, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukun","family":"Li","sequence":"additional","affiliation":[{"name":"Tumor ImmunoMetabolism Institute (TIMI), Zhuzhou Hospital Affiliated to Xiangya School of Medicine, Central South University","place":["Zhuzhou, Hunan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1161\/CIRCRESAHA.113.302095","article-title":"Cardiac metabolism and its interactions with contraction, growth, and survival of cardiomyocytes","volume":"113","author":"Kolwicz","year":"2013","journal-title":"Circ Res"},{"key":"B2","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1161\/CIRCRESAHA.118.312017","article-title":"Metabolic coordination of physiological and pathological cardiac remodeling","volume":"123","author":"Gibb","year":"2018","journal-title":"Circ Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41569-022-00806-6","article-title":"Regression of cardiac hypertrophy in health and disease: mechanisms and therapeutic potential","volume":"20","author":"Martin","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1161\/CIRCRESAHA.112.268128","article-title":"Cardiac-specific deletion of acetyl CoA carboxylase 2 prevents metabolic remodeling during pressure-overload hypertrophy","volume":"111","author":"Kolwicz","year":"2012","journal-title":"Circ Res"},{"key":"B5","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1161\/CIRCRESAHA.113.300376","article-title":"Cardiac metabolism in heart failure: implications beyond ATP production","volume":"113","author":"Doenst","year":"2013","journal-title":"Circ Res"},{"key":"B6","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1161\/CIRCRESAHA.119.315483","article-title":"Metabolic remodeling promotes cardiac hypertrophy by directing glucose to aspartate biosynthesis","volume":"126","author":"Ritterhoff","year":"2020","journal-title":"Circ Res"},{"key":"B7","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.cmet.2020.12.003","article-title":"The pyruvate-lactate axis modulates cardiac hypertrophy and heart failure","volume":"33","author":"Cluntun","year":"2021","journal-title":"Cell Metab"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e150595","DOI":"10.1172\/JCI150595","article-title":"YAP mediates compensatory cardiac hypertrophy through aerobic glycolysis in response to pressure overload","volume":"132","author":"Kashihara","year":"2022","journal-title":"J Clin Invest"},{"key":"B9","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1161\/CIRCRESAHA.124.324650","article-title":"Cardiomyocyte PANX1 controls glycolysis and neutrophil recruitment in hypertrophy","volume":"135","author":"Pavelec","year":"2024","journal-title":"Circ Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e70022","DOI":"10.1111\/jcmm.70022","article-title":"Lactate regulates pathological cardiac hypertrophy via histone lactylation modification","volume":"28","author":"Zhao","year":"2024","journal-title":"J Cell Mol Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1161\/CIRCRESAHA.117.311002","article-title":"Cardiovascular metabolomics","volume":"122","author":"McGarrah","year":"2018","journal-title":"Circ Res"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1161\/CIRCULATIONAHA.122.061846","article-title":"Myocardial metabolomics of human heart failure with preserved ejection fraction","volume":"147","author":"Hahn","year":"2023","journal-title":"Circulation"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1016\/j.cmet.2024.06.003","article-title":"Human cardiac metabolism","volume":"36","author":"Bornstein","year":"2024","journal-title":"Cell Metab"},{"key":"B14","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1161\/CIRCRESAHA.119.316358","article-title":"Fueling cardiac hypertrophy","volume":"126","author":"Matsuura","year":"2020","journal-title":"Circ Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1038\/s41467-023-36712-9","article-title":"The KLF7\/PFKL\/ACADL axis modulates cardiac metabolic remodelling during cardiac hypertrophy in male mice","volume":"14","author":"Wang","year":"2023","journal-title":"Nat Commun"},{"key":"B16","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1161\/CIRCRESAHA.123.322729","article-title":"Protein kinase A is a master regulator of physiological and pathological cardiac hypertrophy","volume":"134","author":"Bai","year":"2024","journal-title":"Circ Res"},{"key":"B17","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1161\/CIRCRESAHA.124.325262","article-title":"Cardiomyocyte PRL2 promotes cardiac hypertrophy via directly dephosphorylating AMPK\u03b12","volume":"136","author":"Han","year":"2025","journal-title":"Circ Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"6668","DOI":"10.1038\/s41467-025-61901-z","article-title":"Cardiomyocyte OTUD1 drives diabetic cardiomyopathy via directly deubiquitinating AMPK\u03b12 and inducing mitochondrial dysfunction","volume":"16","author":"Han","year":"2025","journal-title":"Nat Commun"},{"key":"B19","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1161\/CIRCRESAHA.123.321872","article-title":"Ketones and the heart: metabolic principles and therapeutic implications","volume":"132","author":"Matsuura","year":"2023","journal-title":"Circ Res"},{"key":"B20","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1038\/s12276-023-00958-6","article-title":"Evogliptin, a DPP-4 inhibitor, prevents diabetic cardiomyopathy by alleviating cardiac lipotoxicity in db\/db mice","volume":"55","author":"Pham","year":"2023","journal-title":"Exp Mol Med"},{"key":"B21","doi-asserted-by":"publisher","first-page":"4989","DOI":"10.7150\/thno.107367","article-title":"Inhibition of CAV1 attenuates diabetic cardiomyopathy through reducing ferroptosis via activating NRF2\/GCLC signaling pathway","volume":"15","author":"Li","year":"2025","journal-title":"Theranostics"},{"key":"B22","doi-asserted-by":"publisher","first-page":"907757","DOI":"10.3389\/fendo.2022.907757","article-title":"Signaling pathways related to oxidative stress in diabetic cardiomyopathy","volume":"13","author":"Peng","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1161\/CIRCRESAHA.121.318241","article-title":"Cardiac energy metabolism in heart failure","volume":"128","author":"Lopaschuk","year":"2021","journal-title":"Circ Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1093\/cvr\/cvae231","article-title":"Advances in myocardial energy metabolism: metabolic remodelling in heart failure and beyond","volume":"120","author":"Sun","year":"2024","journal-title":"Cardiovasc Res"},{"key":"B25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1093\/cvr\/cvaa319","article-title":"The role of CD36 in cardiovascular disease","volume":"118","author":"Shu","year":"2022","journal-title":"Cardiovasc Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1161\/CIRCRESAHA.120.315913","article-title":"Basic mechanisms of diabetic heart disease","volume":"126","author":"Ritchie","year":"2020","journal-title":"Circ Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"103184","DOI":"10.1016\/j.redox.2024.103184","article-title":"Sirt5 improves cardiomyocytes fatty acid metabolism and ameliorates cardiac lipotoxicity in diabetic cardiomyopathy via CPT2 de-succinylation","volume":"73","author":"Wu","year":"2024","journal-title":"Redox Biol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"e13761","DOI":"10.1002\/jcsm.13761","article-title":"Therapeutic targeting of Decr1 ameliorates cardiomyopathy by suppressing mitochondrial fatty acid oxidation in diabetic mice","volume":"16","author":"Lu","year":"2025","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B29","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.3390\/ijms23073587","article-title":"Pathophysiology and treatment of diabetic cardiomyopathy and heart failure in patients with diabetes Mellitus","volume":"23","author":"Nakamura","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B30","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1161\/CIRCULATIONAHA.123.066542","article-title":"Novel pan-ERR agonists ameliorate heart failure through enhancing cardiac fatty acid metabolism and mitochondrial function","volume":"149","author":"Xu","year":"2024","journal-title":"Circulation"},{"key":"B31","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/s44161-022-00117-6","article-title":"Integrated landscape of cardiac metabolism in end-stage human nonischemic dilated cardiomyopathy","volume":"1","author":"Flam","year":"2022","journal-title":"Nat Cardiovasc Res"},{"key":"B32","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41422-023-00844-w","article-title":"\u03b1-myosin heavy chain lactylation maintains sarcomeric structure and function and alleviates the development of heart failure","volume":"33","author":"Zhang","year":"2023","journal-title":"Cell Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"101413","DOI":"10.1016\/j.drup.2026.101413","article-title":"ENO1 Lactylation drives bevacizumab resistance through metabolic reprogramming and angiogenesis in ovarian cancer","volume":"87","author":"Zeng","year":"2026","journal-title":"Drug Resist Updat"},{"key":"B34","doi-asserted-by":"publisher","first-page":"e2406026","DOI":"10.1002\/advs.202406026","article-title":"Aloe emodin alleviates radiation-induced heart disease via blocking P4HB lactylation and mitigating kynurenine metabolic disruption","volume":"11","author":"Ouyang","year":"2024","journal-title":"Adv Sci (Weinh)"},{"key":"B35","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40364-026-00898-z","article-title":"Lactate-lactylation in tumor angiogenesis and progression: mechanisms, biomarker potential, and therapeutic implications","volume":"14","author":"Wu","year":"2026","journal-title":"Biomark Res"},{"key":"B36","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1161\/CIRCULATIONAHA.121.055727","article-title":"DYRK1B-STAT3 Drives cardiac hypertrophy and heart failure by impairing mitochondrial bioenergetics","volume":"145","author":"Zhuang","year":"2022","journal-title":"Circulation"},{"key":"B37","doi-asserted-by":"publisher","first-page":"102788","DOI":"10.1016\/j.redox.2023.102788","article-title":"Bmal1 downregulation leads to diabetic cardiomyopathy by promoting Bcl2\/IP3R-mediated mitochondrial ca(2+) overload","volume":"64","author":"Zhang","year":"2023","journal-title":"Redox Biol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1161\/CIRCRESAHA.123.324026","article-title":"MICU3 Regulates mitochondrial calcium and cardiac hypertrophy","volume":"135","author":"Roman","year":"2024","journal-title":"Circ Res"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1161\/CIRCULATIONAHA.124.072661","article-title":"FMO2 Prevents pathological cardiac hypertrophy by maintaining the ER-mitochondria association through interaction with IP3R2-Grp75-VDAC1","volume":"151","author":"Xiao","year":"2025","journal-title":"Circulation"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.3390\/genes14101876","article-title":"Role of mitochondrial dynamics in heart diseases","volume":"14","author":"Tokuyama","year":"2023","journal-title":"Genes (Basel)"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1161\/CIRCULATIONAHA.123.064489","article-title":"FARS2 Deficiency causes cardiomyopathy by disrupting mitochondrial homeostasis and the mitochondrial quality control system","volume":"149","author":"Li","year":"2024","journal-title":"Circulation"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.1161\/CIRCRESAHA.118.314607","article-title":"Mitophagy is essential for maintaining cardiac function during high fat diet-induced diabetic cardiomyopathy","volume":"124","author":"Tong","year":"2019","journal-title":"Circ Res"},{"key":"B43","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1515\/jtim-2025-0030","article-title":"Mitochondrial quality control as a therapeutic target in cardiovascular disease: Mechanistic insights and future directions","volume":"13","author":"Zhang","year":"2025","journal-title":"J Transl Int Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"103855","DOI":"10.1016\/j.redox.2025.103855","article-title":"Tectorigenin attenuates cardiac hypertrophy via USP9X\/MCL1-mediated mitochondrial stabilization","volume":"86","author":"Chen","year":"2025","journal-title":"Redox Biol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41392-024-01816-1","article-title":"2-APQC, A small-molecule activator of sirtuin-3 (SIRT3), alleviates myocardial hypertrophy and fibrosis by regulating mitochondrial homeostasis","volume":"9","author":"Peng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B46","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abd7064","article-title":"Nicotinamide for the treatment of heart failure with preserved ejection fraction","volume":"13","author":"Abdellatif","year":"2021","journal-title":"Sci Transl Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1161\/CIRCRESAHA.120.317046","article-title":"NAD(+) repletion reverses heart failure with preserved ejection fraction","volume":"128","author":"Tong","year":"2021","journal-title":"Circ Res"},{"key":"B48","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1161\/CIRCRESAHA.121.318988","article-title":"SIRT6 Mitigates heart failure with preserved ejection fraction in diabetes","volume":"131","author":"Wu","year":"2022","journal-title":"Circ Res"},{"key":"B49","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jare.2024.04.030","article-title":"Sodium-glucose exchanger 2 inhibitor canagliflozin promotes mitochondrial metabolism and alleviates salt-induced cardiac hypertrophy via preserving SIRT3 expression","volume":"70","author":"Zhao","year":"2025","journal-title":"J Adv Res"},{"key":"B50","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.yjmcc.2024.07.008","article-title":"NAD Metabolism and heart failure: mechanisms and therapeutic potentials","volume":"195","author":"Walker","year":"2024","journal-title":"J Mol Cell Cardiol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s10020-024-00783-1","article-title":"\u03b1-Ketoglutarate improves cardiac insufficiency through NAD(+)-SIRT1 signaling-mediated mitophagy and ferroptosis in pressure overload-induced mice","volume":"30","author":"Yu","year":"2024","journal-title":"Mol Med"},{"key":"B52","doi-asserted-by":"publisher","first-page":"115977","DOI":"10.1016\/j.isci.2026.115977","article-title":"ESM1 Drives cisplatin resistance and ferroptosis resistance via ERBB2\/FAK\/SRC\/HSPB1\/NF-\u03baB signaling in ovarian cancer","volume":"29","author":"Zhang","year":"2026","journal-title":"iScience"},{"key":"B53","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1161\/CIRCULATIONAHA.115.020226","article-title":"Catabolic defect of branched-chain amino acids promotes heart failure","volume":"133","author":"Sun","year":"2016","journal-title":"Circulation"},{"key":"B54","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1161\/CIRCRESAHA.121.319817","article-title":"Mitochondrial H(2)S regulates BCAA catabolism in heart failure","volume":"131","author":"Li","year":"2022","journal-title":"Circ Res"},{"key":"B55","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/j.cmet.2022.09.008","article-title":"Extra-cardiac BCAA catabolism lowers blood pressure and protects from heart failure","volume":"34","author":"Murashige","year":"2022","journal-title":"Cell Metab"},{"key":"B56","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41569-022-00760-3","article-title":"Branched-chain amino acids in cardiovascular disease","volume":"20","author":"McGarrah","year":"2023","journal-title":"Nat Rev Cardiol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"e031617","DOI":"10.1161\/JAHA.123.031617","article-title":"Circulating branched chain amino acids and cardiometabolic disease","volume":"13","author":"Fine","year":"2024","journal-title":"J Am Heart Assoc"},{"key":"B58","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12933-025-02725-5","article-title":"Impaired cardiac branched-chain amino acid metabolism in a novel model of diabetic cardiomyopathy","volume":"24","author":"Asakura","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"6257","DOI":"10.7150\/thno.105894","article-title":"BCAA Catabolism targeted therapy for heart failure with preserved ejection fraction","volume":"15","author":"Wang","year":"2025","journal-title":"Theranostics"},{"key":"B60","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1161\/CIRCULATIONAHA.125.074700","article-title":"GRSF1 Protects against heart failure by maintaining BCAA homeostasis","volume":"153","author":"Wang","year":"2026","journal-title":"Circulation"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1579477","DOI":"10.3389\/fendo.2025.1579477","article-title":"BCAA Metabolism: the Achilles' Heel of ovarian cancer, polycystic ovary syndrome, and premature ovarian failure","volume":"16","author":"Zeng","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B62","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1161\/CIRCRESAHA.123.322381","article-title":"Indole-3-Propionic acid protects against heart failure with preserved ejection fraction","volume":"134","author":"Wang","year":"2024","journal-title":"Circ Res"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.jacbts.2023.05.013","article-title":"Ketone bodies preserve mitochondria through epigenetics","volume":"8","author":"Mukai","year":"2023","journal-title":"JACC Basic Transl Sci"},{"key":"B64","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1161\/CIRCRESAHA.124.325550","article-title":"The heart has intrinsic ketogenic capacity that mediates NAD(+) therapy in HFpEF","volume":"136","author":"Koay","year":"2025","journal-title":"Circ Res"},{"key":"B65","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12933-025-02707-7","article-title":"Metabolic rewiring and inter-organ crosstalk in diabetic HFpEF","volume":"24","author":"Luo","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1161\/CIRCRESAHA.124.326044","article-title":"Metabolic coordination structures contribute to diabetic myocardial dysfunction","volume":"136","author":"Wu","year":"2025","journal-title":"Circ Res"},{"key":"B67","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1515\/jtim-2025-0049","article-title":"Cardiovascular-kidney-metabolic: Hype or a focus on front-line health?","volume":"13","author":"Cai","year":"2025","journal-title":"J Transl Int Med"},{"key":"B68","doi-asserted-by":"publisher","first-page":"106561","DOI":"10.4330\/wjc.v17.i7.106561","article-title":"Novel cardiac biomarkers and multiple-marker approach in the early detection, prognosis, and risk stratification of cardiac diseases","volume":"17","author":"Bokhari","year":"2025","journal-title":"World J Cardiol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s44324-024-00028-z","article-title":"Recent advances in cardiovascular disease research driven by metabolomics technologies in the context of systems biology","volume":"2","author":"Zhang","year":"2024","journal-title":"NPJ Metab Health Dis"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.126.328300","article-title":"Proteogenomics of hypertrophic cardiomyopathy reveals subtype-specific therapy","volume":"126","author":"Ma","year":"2026","journal-title":"Circ Res"},{"key":"B71","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.3390\/diagnostics15141807","article-title":"Molecular diagnostics in heart failure: from biomarkers to personalized medicine","volume":"15","author":"Tica","year":"2025","journal-title":"Diagnostics (Basel"},{"key":"B72","doi-asserted-by":"publisher","first-page":"2345","DOI":"10.1093\/eurheartj\/ehaf1065","article-title":"Histamine N-methyltransferase upregulation, cardiac hypertrophy, and heart failure","volume":"47","author":"Zhang","year":"2026","journal-title":"Eur Heart J"},{"key":"B73","doi-asserted-by":"publisher","first-page":"H1267","DOI":"10.1152\/ajpheart.00121.2025","article-title":"Cardiac energy substrate utilization in heart failure with preserved ejection fraction: reconciling conflicting evidence on fatty acid and glucose metabolism","volume":"328","author":"Shehadeh","year":"2025","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/j.1365-2362.1988.tb01282.x","article-title":"Skeletal muscle and whole body protein turnover in cardiac cachexia: influence of branched-chain amino acid administration","volume":"18","author":"Morrison","year":"1988","journal-title":"Eur J Clin Invest"},{"key":"B75","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1007\/s10495-026-02376-1","article-title":"Metabolic infexibility across heart failure phenotypes: mechanisms and type-specific therapeutic implications","volume":"31","author":"Chen","year":"2026","journal-title":"Apoptosis"},{"key":"B76","doi-asserted-by":"publisher","first-page":"4159","DOI":"10.3390\/jcm15114159","article-title":"Heart failure with preserved ejection fraction as a multisystem syndrome: a mechanistically anchored endotype framework for precision therapy","volume":"15","author":"Krasi\u0144ska","year":"2026","journal-title":"J Clin Med"},{"key":"B77","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.jacbts.2024.04.008","article-title":"Towards metabolomic-based precision approaches for classifying and treating heart failure","volume":"9","author":"Hahn","year":"2024","journal-title":"JACC Basic Transl Sci"},{"key":"B78","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s40364-024-00578-w","article-title":"Serum metabolite signatures of cardiac function and morphology in individuals from a population-based cohort","volume":"12","author":"Maushagen","year":"2024","journal-title":"Biomark Res"},{"key":"B79","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/s44161-022-00057-1","article-title":"Metabolic characterization of hypertrophic cardiomyopathy in human heart","volume":"1","author":"Wang","year":"2022","journal-title":"Nat Cardiovasc Res"},{"key":"B80","doi-asserted-by":"publisher","first-page":"e181172","DOI":"10.1172\/jci.insight.181172","article-title":"Longitudinal lipidomic profiles of left ventricular mass and left ventricular hypertrophy in American Indians","volume":"9","author":"Chen","year":"2024","journal-title":"JCI Insight"},{"key":"B81","doi-asserted-by":"publisher","first-page":"12568","DOI":"10.3389\/jpps.2024.12568","article-title":"Lipotoxicity as a therapeutic target in obesity and diabetic cardiomyopathy","volume":"27","author":"Nakamura","year":"2024","journal-title":"J Pharm Pharm Sci"},{"key":"B82","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s10741-023-10353-y","article-title":"Metabolic adaptations in pressure overload hypertrophic heart","volume":"29","author":"Wei","year":"2024","journal-title":"Heart Fail Rev"},{"key":"B83","doi-asserted-by":"publisher","first-page":"113093","DOI":"10.1016\/j.exger.2026.113093","article-title":"Metabolomic biomarkers enhance 10-year mortality risk calibration and clinical utility in older heart failure patients: a UK biobank study","volume":"217","author":"Zeng","year":"2026","journal-title":"Exp Gerontol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/bs.pmbts.2026.03.011","article-title":"Artificial intelligence in multi-omics analysis of heart diseases","volume":"222","author":"Nikita","year":"2026","journal-title":"Prog Mol Biol Transl Sci"},{"key":"B85","doi-asserted-by":"publisher","first-page":"R858","DOI":"10.1152\/ajpregu.00357.2017","article-title":"Modeling heart failure risk in diabetes and kidney disease: limitations and potential applications of transverse aortic constriction in high-fat-fed mice","volume":"314","author":"Tan","year":"2018","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s11306-007-0080-4","article-title":"Standard reporting requirements for biological samples in metabolomics experiments: microbial and in vitro biology experiments","volume":"3","author":"Van Der Werf","year":"2007","journal-title":"Metabolomics"},{"key":"B87","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12933-019-0892-3","article-title":"Impaired branched chain amino acid oxidation contributes to cardiac insulin resistance in heart failure","volume":"18","author":"Uddin","year":"2019","journal-title":"Cardiovasc Diabetol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11306-022-01926-3","article-title":"Quality assurance and quality control reporting in untargeted metabolic phenotyping: mQACC recommendations for analytical quality management","volume":"18","author":"Kirwan","year":"2022","journal-title":"Metabolomics"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1912835\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T12:04:47Z","timestamp":1785499487000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1912835\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,31]]},"references-count":88,"alternative-id":["10.3389\/fcvm.2026.1912835"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1912835","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,31]]},"article-number":"1912835"}}